Predictors of punding in Parkinson's disease: Results from a questionnaire survey

Movement Disorders

Volumn 22, Issue 16, 2007, Pages 2339-2345

  Lawrence, Andrew J ^a,b,e   Blackwell, Andrew D ^a   Barker, Roger A ^b,c   Spagnolo, Francesca ^d   Clark, Luke ^a,b   Aitken, Michael R F ^a,b   Sahakian, Barbara J ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e UK   (United Kingdom)

Author keywords

Age of onset; Compulsion; Dopamine; Impulsivity; Side effects

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; APOMORPHINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; NEUROLEPTIC AGENT; PERGOLIDE; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE;

AGED; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HUMAN; IMPULSIVENESS; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; ONSET AGE; OUTPATIENT; PARKINSON DISEASE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PUNDING; QUESTIONNAIRE; SELF REPORT;

AGE FACTORS; AGE OF ONSET; AGED; ANTIPARKINSON AGENTS; BEHAVIOR; BEHAVIORAL SYMPTOMS; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; FEMALE; HOBBIES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; SMOKING; SOCIOECONOMIC FACTORS;

EID: 38549131256     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21702     Document Type: Article

References (37)

1. Friedman JH. Punding on levodopa. Biol Psychiatry 1994;36:350-351.
2. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405.
3. Fernandez HH, Friedman JH. Punding on L-dopa. Mov Disord 1999;14:836-838.
4. Kumar S. Punding in Parkinson's disease related to high-dose levodopa therapy. Neurol India 2005;53:362.
5. Miwa H, Morita S, Nakanishi I, Kondo T. Stereotyped behaviors or punding after quetiapine administration in Parkinson's disease. Park Relat Disord 2004;10:177.
6. Miyasaki JM, Al Hassan K, Lang AE, Voon V. Punding prevalence in Parkinson's disease. Mov Disord 2007;22:1179-1181.
7. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006;59:852-858.
8. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62:1377-1381.
9. Shapiro MA, Chang YL, Munson SK, Okun MS, Fernandez HH. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases. Park Relat Disord 2006;12:392-395.
10. Barratt ES. Impulsiveness and aggression. In: Monahan J, Steadman HE, editors. Violence and mental disorder: developments in risk assessment. Chicago: University of Chicago Press; 1994. p 61-79.
11. Burns GL, Keortge SG, Formea GM, Sternberger LG. Revision of the Padua Inventory of obsessive compulsive disorder symptoms: distinctions between worry, obsessions, and compulsions. Behav Res Ther 1996;34:163-173.
12. Sanavio E. Obsessions and compulsions: the Padua inventory. Behav Res Ther 1988;26:169-177.
13. Abassi ZA, Binah O, Youdim MB. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol 2004;143:371-378.
14. Minguez-Castellanos A, Escamilla-Sevilla F, Katati MJ, et al. Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson's disease: target related effect or selection bias? J Neurol Neurosurg Psychiatry 2005;76:34-39.
15. Fahn S, Elton R, Members of the UPDRS Development Committee. United Parkinson's disease rating scale. In: Fahn S, Marsden C, Calne D, Goldstein M, editors. Recent developments in Parkinson's disease. New Jersey: Macmillan Health Care Publication; 1987. p 153-164.
16. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's disease questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997;26:353-357.
17. Myers JL, Well AD. Research design and statistical analysis, 1st ed. New Jersey: Lawrence Erlbaum Associates; 1995.
18. Cardinal RN, Aitken MRF. ANOVA for the behavioral sciences researcher, 1st ed. New Jersey: Lawrence Erlbaum Associates; 2006. p 114-115.
19. Howell DC. Statistical methods for psychology, 5th ed. Belmont, CA: Duxbury Press; 2002.
20. Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 2006;5:355-363.
21. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880.
22. Swainson R, Rogers RD, Sahakian BJ, Summers BA, Polkey CE, Robbins TW. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 2000;38:596-612.
23. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006;30:1-23.
24. Gibb WR, Lees AJ. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology 1988;38:1402-1406.
25. Radad K, Gille G, Rausch WD. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep 2005;57:701-712.
26. Watts RL. The role of dopamine agonists in early Parkinson's disease. Neurology 1997;49(1, Suppl 1):S34-S48.
27. Menza MA, Golbe LI, Cody RA, Forman NE. Dopamine-related personality traits in Parkinson's disease. Neurology 1993;43(3, Part 1):505-508.
28. Kaasinen V, Aalto S, Nagren K, Rinne JO. Insular dopamine D2 receptors and novelty seeking personality in Parkinson's disease. Mov Disord 2004;19:1348-1351.
29. Menza M. The personality associated with Parkinson's disease. Curr Psychiatry Rep 2000;2:421-426.
30. Menza MA, Forman NE, Goldstein HS, Golbe LI. Parkinson's disease, personality, and dopamine. J Neuropsychiatry Clin Neurosci 1990;2:282-287.
31. Tomer R, Aharon-Peretz J. Novelty seeking and harm avoidance in Parkinson's disease: effects of asymmetric dopamine deficiency. J Neurol Neurosurg Psychiatry 2004;75:972-975.
32. Fujii C, Harada S, Ohkoshi N, Hayashi A, Yoshizawa K. Cross-cultural traits for personality of patients with Parkinson's disease in Japan. Am J Med Genet 2000;96:1-3.
33. Benedetti MD, Bower JH, Maraganore DM, et al. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology 2000;55:1350-1358.
34. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005;65:1570-1574.
35. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003;2:595-604.
36. Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006;66:1750-1752.
37. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006;63:969-973.